title: Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy.
abstract: BACKGROUND
  Bleeding is a major limitation of antithrombotic therapy among invasively managed non-ST-segment elevation acute coronary syndromes (NSTE-ACS) patients; therefore, we examined the use of radial access and its association with outcomes among NSTE-ACS patients.
  
  
  METHODS
  Clinical characteristics and geographic variation in radial access were examined, as well as its association with bleeding, red blood cell transfusion and ischemic outcomes (96-hour death/myocardial infarction/recurrent ischemic/thrombotic bailout; 30-day death/myocardial infarction; 1-year death) in the EARLY versus delayed, provisional eptifibatide in acute coronary syndromes trial.
  
  
  RESULTS
  Of 9126 patients, 13.5% underwent radial-access catheterization. Female sex, age, weight, and prior revascularization were inversely associated with radial access, and its use varied widely by country (2%-97%). There were fewer GUSTO severe/moderate bleeds and red blood cell transfusions in the radial access group; however, it was attenuated after adjustment (odds ratio 0.73, 95% confidence intervals [CI] [0.50-1.06], P = .094 and 1.00 [0.71-1.40] P = .991). Ischemic outcomes did not differ by access site.
  
  
  CONCLUSIONS
  In this post hoc analysis of a large clinical trial, there was significant international variation in use of radial access for NSTE-ACS patients undergoing invasive management, and it was preferentially used in those at lower risk for bleeding. Radial approach was not associated with a significant reduction in either bleeding or ischemic outcomes. Further study is needed to determine whether wider application of radial approach to acute coronary syndrome patients at high risk for bleeding improves overall outcomes.
authors.affiliation: Shaare Zedek Medical Center, Jerusalem, Israel.
authors.forename: Marc W
authors.initials: MW
authors.lastname: Klutstein
authors.forename: Cynthia M
authors.initials: CM
authors.lastname: Westerhout
authors.forename: Paul W
authors.initials: PW
authors.lastname: Armstrong
authors.forename: Robert P
authors.initials: RP
authors.lastname: Giugliano
authors.forename: Basil S
authors.initials: BS
authors.lastname: Lewis
authors.forename: C Michael
authors.initials: CM
authors.lastname: Gibson
authors.forename: Sohrab
authors.initials: S
authors.lastname: Lutchmedial
authors.forename: Petr
authors.initials: P
authors.lastname: Widimsky
authors.forename: P Gabriel
authors.initials: PG
authors.lastname: Steg
authors.forename: Anthony
authors.initials: A
authors.lastname: Dalby
authors.forename: Uwe
authors.initials: U
authors.lastname: Zeymer
authors.forename: Frans
authors.initials: F
authors.lastname: Van de Werf
authors.forename: Robert A
authors.initials: RA
authors.lastname: Harrington
authors.forename: L Kristin
authors.initials: LK
authors.lastname: Newby
authors.forename: Sunil V
authors.initials: SV
authors.lastname: Rao
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D000368:Aged; D006328:Cardiac Catheterization / Q000009:adverse effects / Q000379:methods*; D000077542:Eptifibatide; D017707:Erythrocyte Transfusion; D005260:Female; D005269:Femur / Q000002:abnormalities; D006470:Hemorrhage / Q000453:epidemiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use; D010855:Pierre Robin Syndrome; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D057216:Propensity Score; D017534:Radial Artery
chemical_list: D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077542:Eptifibatide